Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26679674 | 1.00 | CA12 (0.59) | CA12CA1CA2CA3CA4 | |
| SCHEMBL10911759 | 0.81 | AGER (0.59) | CA12CA9MMP1MMP2MMP3 | |
| SCHEMBL14798295 | 0.80 | ADAMTS4 (0.58) | MMP2MMP9MMP13 | |
| SCHEMBL12907960 | 0.80 | ADAMTS4 (0.58) | MMP2MMP9MMP13 | |
| SCHEMBL16894214 | 0.80 | ADAMTS4 (0.50) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL16894216 | 0.80 | ADAMTS4 (0.50) | MMP1MMP2MMP3MMP7MMP9 | |
| SCHEMBL8141534 | 0.78 | CA9 (0.56) | CA12CA1CA2CA3CA4 | |
| SCHEMBL9815649 | 0.78 | CA1 (0.67) | CA12CA1CA2CA3CA4 | |
| SCHEMBL14307988 | 0.77 | ADAMTS5 (0.67) | CA12CA1CA2CA3CA4 | |
| SCHEMBL8446545 | 0.77 | ADAMTS4 (0.48) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220380380-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380380-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CA12 4357/4885CA1 4734/4885CA2 4208/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | CA12 4357/4885CA1 4734/4885CA2 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.